Physician profile
Van Millin
NPI 1275682247
$1,379.08
in general payments reported to CMS, 2019-2025
19 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.43 · 2020: $104 · 2022: $34.29 · 2023: $215 · 2024: $445 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.69 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.98 | 2023-2025 | |
| Astellas Pharma US INC | $184.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $177.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $151.70 | 2024-2025 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $96.00 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $82.43 | 2024-2025 | Auvelity, Symbravo |
| Novo Nordisk INC | $74.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Ani Pharmaceuticals, INC. | $67.06 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $55.34 | 2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $52.31 | 2025 | |
| Dexcom, INC. | $45.86 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.20 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $34.23 | 2024 | Yupelri |
| Abbott Laboratories | $24.93 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $18.46 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $14.41 | 2025 | |
| Lilly USA, LLC | $14.35 | 2023 | Mounjaro |
| Boston Scientific Corporation | $14.07 | 2024 | Bodyguardian |
| Exact Sciences Corporation | $13.08 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Millin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.